Takeda In-Licenses Teva's Copaxone As Japan Orphan Drug
This article was originally published in PharmAsia News
Takeda Pharmaceutical reached an agreement with Teva Pharmaceutical Industries to in-license, obtain approval and market Copaxone (glatiramer) for treating multiple sclerosis.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.